TherapeuticsMD, Inc. (TXMD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

-25M 0 25M 50M 75M Q1 '11: 485.9K Q2 '11: 508.3K Q3 '11: 2.1K Q4 '11: 554.4K Q1 '12: 721.7K Q2 '12: 819.1K Q3 '12: 1M Q4 '12: 1.2K Q1 '13: 1.5M Q2 '13: 2.1M Q3 '13: 2.3M Q4 '13: 2.9K Q1 '14: 2.8M Q2 '14: 3.8M Q3 '14: 4.2M Q4 '14: 4.3M Q1 '15: 4.5M Q2 '15: 4.8M Q3 '15: 5.2M Q4 '15: 5.6M Q1 '16: 4.9M Q2 '16: 4.4M Q3 '16: 5.5M Q4 '16: 4.5M Q1 '17: 4M Q2 '17: 4.2M Q3 '17: 4.4M Q4 '17: 4.1M Q1 '18: 3.8M Q2 '18: 3.8M Q3 '18: 3.5M Q4 '18: 5.1M Q1 '19: 3.9M Q2 '19: 6.1M Q3 '19: 23.7M Q4 '19: 15.9M Q1 '20: 12.3M Q2 '20: 10.7M Q3 '20: 19.3M Q4 '20: 22.6M Q1 '21: 19.9M Q2 '21: 23M Q3 '21: 25.4M Q4 '21: 18.7M Q1 '22: 19.3M Q2 '22: 28.6M Q3 '22: 354K Q4 '22: 68.6M Q1 '23: 416K Q2 '23: 437K Q3 '23: -53K Q4 '23: 502K Q1 '24: 313K Q2 '24: 234K Q3 '24: 547K Q4 '24: 667K Q1 '25: 393K Q2 '25: 952K Q3 '25: 784K Q4 '25: 893K Q1 '26: 724K Q2 '26: 869K Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Gross Profit Quarterly

-25M 0 25M 50M 75M Q1 '11: 282.1K Q2 '11: 269.3K Q3 '11: 297.9K Q4 '11: 291.8K Q1 '12: 385.6K Q2 '12: 446.8K Q3 '12: 729.6K Q4 '12: 908 Q1 '13: 1.2M Q2 '13: 1.6M Q3 '13: 1.6M Q4 '13: 2.4K Q1 '14: 2M Q2 '14: 2.9M Q3 '14: 3.1M Q4 '14: 3.4M Q1 '15: 3.4M Q2 '15: 3.8M Q3 '15: 4M Q4 '15: 4.4M Q1 '16: 3.8M Q2 '16: 3.3M Q3 '16: 4.3M Q4 '16: 3.8M Q1 '17: 3.3M Q2 '17: 3.6M Q3 '17: 3.7M Q4 '17: 3.5M Q1 '18: 3.1M Q2 '18: 3.3M Q3 '18: 2.8M Q4 '18: 4.1M Q1 '19: 3.2M Q2 '19: 4.8M Q3 '19: 22.3M Q4 '19: 13M Q1 '20: 9.5M Q2 '20: 6.3M Q3 '20: 16.1M Q4 '20: 17M Q1 '21: 15.2M Q2 '21: 18.9M Q3 '21: 20.1M Q4 '21: 13.9M Q1 '22: 14.5M Q2 '22: 0 Q3 '22: 0 Q4 '22: 68.6M Q1 '23: 416K Q2 '23: 437K Q3 '23: -53K Q4 '23: 502K Q3 '11 Q2 '13 Q1 '15 Q4 '16 Q3 '18 Q2 '20 Q1 '22 Q4 '23

Operating Income Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '11: -771.4K Q2 '11: -1.1M Q3 '11: -1.4M Q4 '11: -2.2M Q1 '12: -2.9M Q2 '12: -4M Q3 '12: -3.9M Q4 '12: -5.4M Q1 '13: -4.9M Q2 '13: -5.6M Q3 '13: -7.2M Q4 '13: -8M Q1 '14: -9M Q2 '14: -10.9M Q3 '14: -17.8M Q4 '14: -16.3M Q1 '15: -20.9M Q2 '15: -27.3M Q3 '15: -19.5M Q4 '15: -17.5M Q1 '16: -21M Q2 '16: -21.2M Q3 '16: -25.1M Q4 '16: -22.9M Q1 '17: -21.3M Q2 '17: -19.8M Q3 '17: -14.8M Q4 '17: -21.7M Q1 '18: -24.7M Q2 '18: -33M Q3 '18: -34.4M Q4 '18: -38.1M Q1 '19: -38.1M Q2 '19: -41.6M Q3 '19: -27.1M Q4 '19: -44.4M Q1 '20: -50.9M Q2 '20: -45M Q3 '20: -25M Q4 '20: -34.6M Q1 '21: -29.3M Q2 '21: -35.2M Q3 '21: -39.9M Q4 '21: -35.4M Q1 '22: -17.9M Q2 '22: -14.9M Q3 '22: -14.5M Q4 '22: 48.4M Q1 '23: -2.7M Q2 '23: -2.5M Q3 '23: -1.8M Q4 '23: -1.6M Q1 '24: -1.1M Q2 '24: -2.8M Q3 '24: -1.1M Q4 '24: -652K Q1 '25: -1.3M Q2 '25: -695K Q3 '25: -862K Q4 '25: -1.6M Q1 '26: -723K Q2 '26: -816K Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Net Income Quarterly

-80M -40M 0 40M 80M 120M Q1 '10: -347.4K Q2 '10: -269.1K Q3 '10: 30K Q4 '10: -2.3M Q1 '11: -774.4K Q2 '11: -1.1M Q3 '11: -1.5M Q4 '11: -9.6M Q1 '12: -13.3M Q2 '12: -11.9M Q3 '12: -4.3M Q4 '12: -5.7K Q1 '13: -6.4M Q2 '13: -6M Q3 '13: -7.7M Q4 '13: -8.4K Q1 '14: -9.2M Q2 '14: -10.9M Q3 '14: -17.8M Q4 '14: -16.3M Q1 '15: -20.9M Q2 '15: -27.2M Q3 '15: -19.5M Q4 '15: -17.5M Q1 '16: -20.9M Q2 '16: -21.1M Q3 '16: -25M Q4 '16: -22.8M Q1 '17: -21.2M Q2 '17: -19.7M Q3 '17: -14.7M Q4 '17: -21.4M Q1 '18: -24.4M Q2 '18: -33.2M Q3 '18: -35.6M Q4 '18: -39.4M Q1 '19: -39.5M Q2 '19: -55.2M Q3 '19: -32M Q4 '19: -49.4M Q1 '20: -56.8M Q2 '20: -52M Q3 '20: -32.6M Q4 '20: -42.1M Q1 '21: -39.4M Q2 '21: -42.7M Q3 '21: -47.4M Q4 '21: -43M Q1 '22: -49M Q2 '22: 112.3M Q3 '22: -29M Q4 '22: 77.7M Q1 '23: -3.6M Q2 '23: -2.4M Q3 '23: -3.4M Q4 '23: -883K Q1 '24: -734K Q2 '24: -1.1M Q3 '24: -609K Q4 '24: 252K Q1 '25: -653K Q2 '25: 551K Q3 '25: 152K Q4 '25: -619K Q1 '26: 95K Q2 '26: 155K Q3 '10 Q4 '12 Q1 '15 Q2 '17 Q3 '19 Q4 '21 Q1 '24 Q2 '26

Cost of Revenue Quarterly

0 2M 4M 6M Q1 '17: 659.6K Q2 '17: 681.7K Q3 '17: 700.8K Q4 '17: 594.8K Q1 '18: 633.6K Q2 '18: 454.2K Q3 '18: 699.1K Q4 '18: 950.8K Q1 '19: 762.8K Q2 '19: 1.2M Q3 '19: 1.4M Q4 '19: 2.9M Q1 '20: 2.7M Q2 '20: 4.4M Q3 '20: 3.3M Q4 '20: 5.6M Q1 '21: 4.7M Q2 '21: 4.1M Q3 '21: 5.3M Q1 '22: 695K Q2 '22: 348K Q3 '22: 354K Q4 '22: 0 Q2 '17 Q1 '18 Q4 '18 Q3 '19 Q2 '20 Q1 '21 Q1 '22 Q4 '22

Operating Cash Flow Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '10: 411.5K Q1 '11: -760.7K Q2 '11: -801.8K Q3 '11: -1.5M Q4 '11: -1.9M Q1 '12: -2.5M Q2 '12: -3.2M Q3 '12: -3.1M Q4 '12: -4M Q1 '13: -3.5M Q2 '13: -7.2M Q3 '13: -5.3M Q4 '13: -4.8M Q1 '14: -8.7M Q2 '14: -10.1M Q3 '14: -11.5M Q4 '14: -15.3M Q1 '15: -19.1M Q2 '15: -24.8M Q3 '15: -18.4M Q4 '15: -16.6M Q1 '16: -19.4M Q2 '16: -15.3M Q3 '16: -18.8M Q4 '16: -15.6M Q1 '17: -20.5M Q2 '17: -18.1M Q3 '17: -16.7M Q4 '17: -20.8M Q1 '18: -19.6M Q2 '18: -24.9M Q3 '18: -34.1M Q4 '18: -28.1M Q1 '19: -38.2M Q2 '19: -50.5M Q3 '19: -26.2M Q4 '19: -50.8M Q1 '20: -39.1M Q2 '20: -56M Q3 '20: -34M Q4 '20: -30.4M Q1 '21: -38.4M Q2 '21: -26.5M Q3 '21: -38.2M Q4 '21: -39.6M Q1 '22: -17.9M Q2 '22: -27.1M Q3 '22: -18.9M Q4 '22: 73.2M Q1 '23: -8.7M Q2 '23: -3.4M Q3 '23: -6M Q4 '23: -5M Q1 '24: -229K Q2 '24: 1.5M Q3 '24: -71K Q4 '24: 17K Q1 '25: 699K Q2 '25: 381K Q3 '25: 999K Q4 '25: 375K Q1 '26: 944K Q2 '26: 779K Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

Free Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q1 '11: -771.6K Q2 '11: -816.8K Q3 '11: -1.5M Q4 '11: -1.9M Q1 '12: -2.5M Q2 '12: -3.2M Q3 '12: -3.1M Q4 '12: -4M Q1 '13: -3.5M Q2 '13: -7.2M Q3 '13: -5.3M Q4 '13: -4.8M Q1 '14: -8.7M Q2 '14: -10.1M Q3 '14: -11.5M Q4 '14: -15.3M Q3 '15: -18.4M Q4 '15: -16.8M Q1 '16: -19.5M Q2 '16: -15.5M Q3 '16: -18.8M Q4 '16: -15.7M Q1 '17: -20.6M Q2 '17: -18.1M Q3 '17: -16.7M Q4 '17: -20.8M Q1 '18: -19.7M Q2 '18: -25M Q3 '18: -34.1M Q4 '18: -28.3M Q1 '19: -38.4M Q2 '19: -51.3M Q3 '19: -27.2M Q4 '19: -51.2M Q1 '20: -39.1M Q2 '20: -56M Q3 '20: -34.1M Q4 '20: -30.5M Q1 '21: -38.4M Q2 '21: -26.6M Q3 '21: -38.3M Q4 '21: -39.6M Q1 '22: -17.9M Q2 '22: -27.1M Q3 '22: -18.9M Q3 '11 Q1 '13 Q3 '14 Q3 '16 Q1 '18 Q3 '19 Q1 '21 Q3 '22

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 100M 200M 300M Q1 '20: 271.5M Q2 '20: 271.9M Q3 '20: 272.6M Q1 '21: 6.9M Q2 '21: 7.9M Q3 '21: 8.4M Q1 '22: 8.6M Q2 '22: 8.8M Q3 '22: 9.3M Q1 '23: 9.8M Q2 '23: 10.2M Q3 '23: 10.7M Q1 '24: 11.5M Q2 '24: 11.5M Q3 '24: 11.5M Q1 '25: 11.6K Q2 '25: 11.6M Q3 '25: 11.6M Q1 '26: 11.6K Q2 '26: 11.6M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q4 '11: -0.21 Q1 '12: -0.36 Q2 '12: -0.48 Q3 '12: -0.49 Q4 '12: -0.40 Q1 '13: -0.30 Q2 '13: -0.21 Q3 '13: -0.23 Q4 '13: -0.23 Q1 '14: -0.23 Q2 '14: -0.25 Q3 '14: -0.31 Q4 '14: -0.35 Q1 '15: -0.42 Q2 '15: -0.51 Q3 '15: -0.50 Q4 '15: -0.50 Q1 '16: -0.48 Q2 '16: -0.43 Q3 '16: -0.45 Q4 '16: -0.47 Q1 '17: -0.47 Q2 '17: -0.46 Q3 '17: -0.40 Q4 '17: -0.38 Q1 '18: -0.38 Q2 '18: -0.43 Q3 '18: -0.52 Q4 '18: -0.59 Q1 '19: -0.64 Q2 '19: -0.72 Q3 '19: -0.69 Q4 '19: -0.71 Q1 '20: -0.34 Q2 '20: -0.30 Q3 '20: -0.29 Q4 '20: -0.25 Q1 '21: -6.13 Q2 '21: -11.35 Q3 '21: -16.85 Q4 '21: -21.68 Q1 '22: -21.71 Q2 '22: -3.47 Q3 '22: -0.98 Q4 '22: 12.10 Q1 '23: 17.43 Q2 '23: 4.36 Q3 '23: 7.17 Q4 '23: -1.00 Q1 '24: -0.69 Q2 '24: -0.54 Q3 '24: -0.27 Q4 '24: -0.19 Q3 '12 Q2 '14 Q1 '16 Q4 '17 Q3 '19 Q2 '21 Q1 '23 Q4 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.